Publications

1. Wainwright DA, Horbinski CM, Hashizume R, James CD. Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. Neurotherapeutics. 2017 Apr;14(2):385-392. PMID: 28321824

 

2. Hartlieb KJ, Ferris DP, Holcroft JM, Kandela I, Stern CL, Nassar MS, Botros YY, Stoddart JF. Encapsulation of Ibuprofen in CD-MOF and Related Bioavailability Studies. Mol Pharm. 2017 May 1;14(5):1831-1839.

 

3. Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles  FJ, Billadeau DD, Mazar AP. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1891-1897.

 

4. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA., Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells, Lab Investigation. 2017 Feb;97(2):176-186.

 

5. Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM., Proteasomal inhibition by Ixazomib CHK1 and MYC-dependent Cell Death in T-cell and Hodgkin Lymphoma, Cancer Research. 2016 76(11): 3319-31.

 

6. Aird F, Kandela I, Mantis C; Reproducibility Project: Cancer Biology. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 2017 Jan 19;6.6. Kandela I, Aird F; Reproducibility Project: Cancer Biology.. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife. 2017 Jan 19;6.

 

7. Kandela I, Aird F; Reproducibility Project: Cancer Biology.. Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Elife. 2017 Jan 19;6.

 

8. Mantis C, Kandela I, Aird F; Reproducibility Project: Cancer Biology.. Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Elife. 2017 Jan 19;6.

 

9. Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 Oct 1;380(2):384-92.

 

10. Dong R, Qiang W, Guo H, Xu X, Kim JJ, Mazar A, Kong B, Wei JJ. Histologic and  molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. J Hematol Oncol. 2016 Sep 21;9(1):92.

 

11. Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D, Mathews J, O'Halloran TV, Wei JJ, Mazar AP. Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors. Neoplasia. 2015 Sep;17(9):735-41.

 

12. Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar AP, Odom TW., Biodistribution and in Vivo Toxicity of Aptamer-Loaded Gold Nanostars, Nanomedicine, Nanomedicine. 2015 Apr;11(3):671-9.

 

13. Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela IK, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen ST, Shanmugam M., Targeting the Metabolic Plasticity of Multiple Myeloma with FDA Approved Ritonavir and Metformin, Clin Cancer Res. 2015 Mar 1;21(5):1161-71.

 

14. Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Sharma J, Kandela IK, Mazar AP, Evens AM., The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models. Clin Cancer Res. 2014 Dec 1;20(23):6023-33.

 

15. Miodragovic D, Quentzel J, Kurutz J, Stern C, Ahn R, Kandela IK, Mazar A, O’Halloran T, Robust structure and reactivity of aqueous arsenous acid-platinum (II) anticancer complexes, Angewandte Chemie, Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10749-52

 

16. Jensen SA1, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, Merkel TJ, Luthi AJ, Patel PC, Cutler JI, Daniel WL, Scott AW, Rotz MW, Meade TJ, Giljohann DA, Mirkin CA, Stegh AH, Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma, Sci Transl Med. 2013 Oct 30; 5(209): 209ra152.

 

17. Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014. PMID: 28564604.

 

18. Sita TL, Kouri FM, Hurley LA, Merkel TJ, Chalastanis A, May JL, Ghelfi ST, Cole LE, Cayton TC, Barnaby SN, Sprangers AJ, Savalia N, James CD, Lee A, Mirkin CA, Stegh AH. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Proc Natl Acad Sci U S A. 2017;114:4129-4134. PMC5402467

 

19. Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.  Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1. PMID: 27370397.

 

20. Yoo JY, Yu JG, Kaka A, Pan Q, Kumar P, Kumar B, Zhang J, Mazar A, Teknos TN, Kaur B, Old MO.. Mol Ther Oncolytics. 2015 May 20;2:15008. doi: 10.1038/mto.2015.8. eCollection 2015.ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. PMID: 27119105.

 

21. Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13. PMID: 25313012.